ACCOUNTS - Final Accounts

Caseware UK (AP4) 2022.0.179 2022.0.179 2022-04-302022-04-301true12021-05-01truefalseBusiness and domestic software developmentThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 11927645 2021-05-01 2022-04-30 11927645 2020-05-01 2021-04-30 11927645 2022-04-30 11927645 2021-04-30 11927645 c:Director1 2021-05-01 2022-04-30 11927645 d:CurrentFinancialInstruments 2022-04-30 11927645 d:CurrentFinancialInstruments 2021-04-30 11927645 d:Non-currentFinancialInstruments 2022-04-30 11927645 d:Non-currentFinancialInstruments 2021-04-30 11927645 d:CurrentFinancialInstruments d:WithinOneYear 2022-04-30 11927645 d:CurrentFinancialInstruments d:WithinOneYear 2021-04-30 11927645 d:Non-currentFinancialInstruments d:AfterOneYear 2022-04-30 11927645 d:Non-currentFinancialInstruments d:AfterOneYear 2021-04-30 11927645 d:ShareCapital 2022-04-30 11927645 d:ShareCapital 2021-04-30 11927645 d:RetainedEarningsAccumulatedLosses 2022-04-30 11927645 d:RetainedEarningsAccumulatedLosses 2021-04-30 11927645 c:OrdinaryShareClass1 2021-05-01 2022-04-30 11927645 c:OrdinaryShareClass1 2022-04-30 11927645 c:OrdinaryShareClass1 2021-04-30 11927645 c:FRS102 2021-05-01 2022-04-30 11927645 c:AuditExempt-NoAccountantsReport 2021-05-01 2022-04-30 11927645 c:FullAccounts 2021-05-01 2022-04-30 11927645 c:PrivateLimitedCompanyLtd 2021-05-01 2022-04-30 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 11927645

BIOCORE LTD

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 APRIL 2022

BIOCORE LTD

REGISTERED NUMBER: 11927645

BALANCE SHEET

AS AT 30 APRIL 2022

		2022		2021
Note		£		£


CURRENT ASSETS
Debtors: amounts falling due within one year	4	-		1
Cash at bank and in hand		22,166		-
		22,166		1
Creditors: amounts falling due within one year	5	(5,435)		-
NET CURRENT ASSETS			16,731		1
TOTAL ASSETS LESS CURRENT LIABILITIES			16,731		1
Creditors: amounts falling due after more than one year	6		(25,000)		-

NET (LIABILITIES)/ASSETS			(8,269)		1

CAPITAL AND RESERVES
Called up share capital	7	1	1
Profit and loss account		(8,270)	-
		(8,269)	1

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

Page 1

BIOCORE LTD

REGISTERED NUMBER: 11927645

BALANCE SHEET (CONTINUED)

AS AT 30 APRIL 2022

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

R Makol

Director

Date: 26 April 2023

The notes on pages 3 to 5 form part of these financial statements.

Page 2

BIOCORE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2022

1.	GENERAL INFORMATION

Biocore Ltd is a private company limited by shares and incorporated in England and Wales. Its registered office address is Salisbury House, Station Road, Cambridge, CB1 2LA.
The Company's functional and presentational currency is GBP.

2.ACCOUNTING POLICIES

2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2

GOING CONCERN

The financial statements have been prepared on the going concern basis which assumes that the Company will continue as a going concern for the forseeable future.
Given the investment received, and in reference to the cash position at the balance sheet date, the director has a reasonable expectation that the Company will be able to meet its liabilities as they fall due for the forseeable future and therefore continues to adopt going concern basis.

2.3

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.4

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.5

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 3

BIOCORE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2022

2.ACCOUNTING POLICIES (CONTINUED)

2.6

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:

∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and

∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

EMPLOYEES

The average monthly number of employees, including directors, during the year was 1 (2021 - 1).

Page 4

BIOCORE LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2022

4.	DEBTORS: AMOUNTS DUE WITHIN ONE YEAR

					2022	2021
					£	£


Other debtors	-	1
	-	1

5.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
		2022	2021
		£	£

Other creditors	3,635	-
Accruals and deferred income	1,800	-
	5,435	-

6.	CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
		2022	2021
		£	£

Other creditors	25,000	-
	25,000	-

Other creditors comprise a convertible loan note, which will convert to equity in the event of a qualifying financing round. The loan note is repayable in the event of a business sale or in the event of it not converting by the longstop date, being 12 months from the date of the agreement.

7.	SHARE CAPITAL
		2022	2021
		£	£

ALLOTTED, CALLED UP AND FULLY PAID

110,600 (2021 - 100,000) Ordinary shares of £0.00001 each	1.11	1.00

On 22 April 2022 , 10,600 Ordinary shares of £0.00001 were issued at par.

Page 5